Kondili, Loreta A. Gaeta, Giovanni Battista Ieluzzi, Donatella Linda Zignego, Anna Monti, Monica Gori, Andrea Soria, Alessandro Raimondo, Giovanni Filomia, Roberto Di Leo, Alfredo Iannone, Andrea Massari, Marco Corsini, Romina Gulminetti, Roberto Comini, Alberto Gatti Toniutto, Pierluigi Dissegna, Denis Russo, Francesco Paolo Zanetto, Alberto Grazia Rumi, Maria Brancaccio, Giuseppina Danieli, Elena Rossana Brunetto, Maurizia Weimer, Liliana Elena Giovanna Quaranta, Maria Vella, Stefano Puoti, Massimo Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients. <p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p> anti-HCV direct-acting antivirals;HepC Drug Interactions;moderate-to-severe liver disease;PITER Cohort Study Background;DDI;liver disease;comedication;363 patients;drug-drug interactions;DAA;moderate-to-severe disease 2017-02-28
    https://plos.figshare.com/articles/figure/Number_of_co-medications_used_and_percentage_of_patients_by_DAA_regimen_among_HCV-infected_patients_/4703239
10.1371/journal.pone.0172159.g001